Table 3.
Serum (ng/ml) | Urine (μg/mmol creatinine) | |||||
Odds ratio | 95% confidence interval | P value | Odds ratio | 95% confidence interval | P value | |
Full study | (219 cases/891 controls) | (198 cases/797 controls) | ||||
Total isoflavones | 1.03 | 0.95 to 1.11 | 0.479 | 1.08 | 1.00 to 1.16 | 0.055 |
Total lignans | 0.99 | 0.90 to 1.08 | 0.728 | 1.01 | 0.94 to 1.09 | 0.758 |
Daidzein | 1.04 | 0.98 to 1.10 | 0.225 | 1.05 | 0.99 to 1.10 | 0.096 |
Equol | 1.04 | 0.98 to 1.10 | 0.167 | 1.03 | 0.99 to 1.06 | 0.131 |
o-Desmethylangolensin | 1.03 | 0.97 to 1.09 | 0.390 | 1.02 | 0.98 to 1.06 | 0.250 |
Genistein | 1.00 | 0.94 to 1.05 | 0.911 | 1.01 | 0.97 to 1.05 | 0.706 |
Glycitein | 1.03 | 0.97 to 1.10 | 0.345 | 1.03 | 0.98 to 1.07 | 0.248 |
Enterodiol | 1.02 | 0.96 to 1.09 | 0.461 | 1.01 | 0.96 to 1.05 | 0.772 |
Enterolactone | 0.98 | 0.91 to 1.05 | 0.564 | 0.99 | 0.94 to 1.04 | 0.718 |
Oestrogen receptor-positive subgroup | (105 cases/365 controls) | (95 cases/329 controls) | ||||
Total isoflavones | 1.01 | 0.91 to 1.12 | 0.818 | 1.09 | 0.97 to 1.22 | 0.154 |
Total lignans | 1.02 | 0.89 to 1.17 | 0.774 | 1.12 | 0.99 to 1.28 | 0.083 |
Daidzein | 1.05 | 0.97 to 1.13 | 0.260 | 1.03 | 0.96 to 1.10 | 0.468 |
Equol | 1.01 | 0.93 to 1.09 | 0.887 | 1.07 | 1.01 to 1.12 | 0.013 |
o-Desmethylangolensin | 1.05 | 0.96 to 1.14 | 0.314 | 1.04 | 0.98 to 1.10 | 0.192 |
Genistein | 0.99 | 0.92 to 1.06 | 0.775 | 1.00 | 0.94 to 1.05 | 0.882 |
Glycitein | 1.03 | 0.93 to 1.13 | 0.614 | 1.04 | 0.98 to 1.10 | 0.186 |
Enterodiol | 1.00 | 0.92 to 1.09 | 0.990 | 1.04 | 0.98 to 1.11 | 0.235 |
Enterolactone | 1.01 | 0.91 to 1.14 | 0.806 | 1.08 | 0.98 to 1.19 | 0.115 |
Values are log2-transformed and adjusted for weight, oral contraceptive use, menopausal hormone treatment, menopausal status, parity, menarche, breastfeeding, family history of breast cancer, daily intake of fat and energy, and batch.